Cargando…
Corrigendum to: Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244916/ https://www.ncbi.nlm.nih.gov/pubmed/35785403 http://dx.doi.org/10.1177/17562864221100917 |
Ejemplares similares
-
Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
por: Wang, Hao, et al.
Publicado: (2021) -
Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience
por: Jade, Jui Dilip, et al.
Publicado: (2017) -
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
por: Nosadini, Margherita, et al.
Publicado: (2016) -
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
por: Marcinnò, Andrea, et al.
Publicado: (2018) -
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)